National Comprehensive Cancer Network

INVESTIGATOR

MEMBER INSTITUTION

STUDY

Patrick J. Creaven, MD, PhD

Roswell Park Cancer Institute

Phase I Study of Irinotecan followed by Capecitabine in Patients with Advanced Breast Carcinoma

Stacy Moulder, MD

H. Lee Moffitt Cancer Center & Research Institute

A Single Arm Phase II Study of Gemcitabine and Irinotecan in Patients with Metastatic Breast Cancer

Pedro Ramirez, MD

The University of Texas M.D. Anderson Cancer Center

Phase I Trial of Concurrent Weekly CPT-11, Cisplatinum, and Radiotherapy for Patients with Newly Diagnosed Stage IIIb-IVa Cancer of the Uterine Cervix

M. Wasif Saif, MD, MBBS

University of Alabama at Birmingham Comprehensive Cancer Center

A Phase I and Pharmacologic Trial of Sequential Administration of Bi-weekly Gemcitabine as a 24-hour IV Infusion followed by Irinotecan as a 24-hour IV Infusion in Adult Cancer Patients

Charles Shapiro, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Phase II Study of Sequentially Administered Mitomycin and Irinotecan in Patients with Refractory Metastatic and Inflammatory Breast Cancers

INVESTIGATOR

MEMBER INSTITUTION

STUDY

Manuel Hidalgo, MD, PhD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Biological Evaluation of Celecoxib in Pancreatic Cancer

Milind Javle, MD

Roswell Park Cancer Institute

Celecoxib in Combination with Irinotecan (CPT-11), 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer.  A Phase I Study

Ritsuko Komaki, MD, FACR

The University of Texas M.D. Anderson Cancer Center

A Phase I Study of Concurrent CPT-11/Cisplatin and Celecoxib with Radiation Therapy for Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC)

Nancy Lewis, MD

Fox Chase Cancer Center

A Randomized Trial of Celecoxib +/- Rosiglitazone vs. Placebo in Patients with Early Stage Non-Invasive Bladder Carcinoma

Brian Rini, MD

UCSF Helen Diller Family Comprehensive Cancer Center

A Phase II Trial of Celecoxib Plus Interferon-Alpha in Advanced Renal Cell Carcinoma 

Manisha Shah, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma

Charles Shapiro, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

A Phase II Trial of Exemestane (Aromasin) in Combination with Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women with Stage II, III, and IV Breast Cancer

Przemyslaw Twardowski, MD

City of Hope Comprehensive Cancer Center

Biologic Markers of Angiogenesis: A Companion Study to Phase I Trial of Oral Etoposide in Combination with Celecoxib in Patients with Advanced Malignancies and Phase I Trial of Oral Cyclophosphamide in Combination with Celecoxib in Patients with Advanced Malignancies

INVESTIGATOR

MEMBER INSTITUTION

STUDY

Tanios Bekaii-Saab, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients with Advanced Pancreatic Cancer

Renuka Iyer, MD

Roswell Park Cancer Institute

Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer

Milind Javle, MD

Roswell Park Cancer Institute

Phase II Study of Capecitabine in Combination with Oxaliplatin and Radiotherapy for Esophageal and Gastroesophageal Junction Cancer

Andrew Ko, MD

UCSF Helen Diller Family Comprehensive Cancer Center

A Phase I Study, with expanded cohort, of Biweekly Fixed-Dose Rate Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic and Biliary Carcinomas

Wells Messersmith, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Thymidylate Synthase (TS) Genotype-Directed Phase II Trial of Oral Capecitabine for 2nd Line Treatment of Advanced Pancreatic Cancer

Mary Mulcahy, MD

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

A Phase II Study of Capecitabine and Oxaliplatin with Radiation for Esophageal and Gastroesophageal Junction Adenocarcinoma

Lakshmi Pendyala, PhD

Roswell Park Cancer Institute

Gene Expression Profiling of Esophageal Cancer in Patients Receiving Oxaliplatin, Capecitabine and Radiation, Exploring Correlations to Response

M. Wasif Saif, MD, MBBS

Yale University School of Medicine

A Phase I/II, Open-Label, Dose Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients with Advanced Pancreatic Carcinoma

Robert Warren, MD

UCSF Helen Diller Family Comprehensive Cancer Center

A Retrospective Analysis of Thymidylate Synthase (TS) and Thymidine Phosphorylase (TP) Levels and Thymidylate Synthase (TS) Genetic Polymorphisms from Archived Hepatocellular Carcinoma (HCC) Surgical Specimens

INVESTIGATOR

MEMBER INSTITUTION

STUDY

Long Dang, MD, PhD

University of Michigan Comprehensive Cancer Center

Targeting Tumor Reactive Response to Antiangiogenic Therapy

Frank Fitzpatrick, PhD

Huntsman Cancer Institute at the University of Utah

Molecular Determinants of Sunitinib Efficacy

Roberto Pili, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Vertical Inhibition of the VEGF Pathway with Sunitinib in Combination with HDAC and mTOR Inhibitors in Renal Cell Carcinoma Models

Sabina Signoretti, MD and
James Mier, MD

Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center

Therapy of Renal Cell Carcinoma with Sutent: Mechanism of Acquired Resistance

John Sunwoo, MD, FACS

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Preclinical Evaluation of Sunitinib in Squamous Cell Carcinoma of the Head and Neck

Michael Wong, MD, PhD, FRCPC

Roswell Park Cancer Institute 

Inhibition of Human Angiosarcoma and Reversal of Chemoresistance by Sunitinib

Sam Yoon, MD

Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center

Sunitinib with and without Radiation Therapy: Analysis in a Novel Mouse Model of Soft Tissue Sarcomas

INVESTIGATOR

MEMBER INSTITUTION

STUDY

John Hoffman, MD

Huntsman Cancer Institute at the University of Utah

Sunitinib for Metastatic Renal Cell Cancer with Imaging Biomarker Assessments for the Early Prediction of Tumor Response

Robert G. Maki, MD, PhD

Memorial Sloan-Kettering Cancer Center

18FDG-PET As a Means to Determine Clinical Response in Soft Tissue Sarcomas in Patients Receiving a Continuous Daily Dosing Schedule of Sunitinib

Andrew Quon, MD

Stanford Comprehensive Cancer Center

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using FDG PET/CT, MRI, and DEC MRI

Jennifer Specht, MD

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

DCE-MRI and FDG-PET with Kinetic Analysis to Monitor Breast Cancer Response to Neoadjuvant Sunitinib and Metronomic Chemotherapy

INVESTIGATOR

MEMBER INSTITUTION

STUDY

Mihaela Cristea, MD

City of Hope Comprehensive Cancer Center

Phase I Trial of Intraperitoneal nab-paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Grace Dy, MD

Roswell Park Cancer Institute

SPARC Expression in NSCLC is Correlated with Response to nab-paclitaxel

Matthew G. Fury, MD, PhD

Memorial Sloan-Kettering Cancer Center

Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (AbraxaneŽ) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients with Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

Thomas Olencki, DO

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

A Phase 2 Study of Weekly Infusion nab-paclitaxel (paclitaxel protein-bound particles for injectable suspension) in Patients with Unresectable and Metastatic Uveal Melanoma

Gregory A. Otterson, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Phase II Trial of Abraxane plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding from VEGF Directed Therapies

COORDINATING CENTER/PROJECT CHAIR

PARTICIPATING MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR

STUDY

University of Michigan Comprehensive Cancer Center/Maha Hussain, MD, FACP

City of Hope Comprehensive Cancer Center/Przemyslaw Twardowski, MD

Phase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma

Huntsman Cancer Institute at the University of Utah/Neeraj Agarwal, MD

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/Evan Yu, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/Mario Eisenberger, MD

Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Gary MacVicar, MD

Roswell Park Cancer Institute/Ellis Levine, MD

Stanford Comprehensive Cancer Center/Sandy Srinivas, MD

The University of Texas M.D. Anderson Cancer Center/Arlene Siefker-Radtke, MD

Vanderbilt-Ingram Cancer Center/Bruce Roth, MD

Memorial Sloan-Kettering Cancer Center/Matthew Fury, MD, PhD

City of Hope Comprehensive Cancer Center/Dean Lim, MD

A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Robert H. Lurie Comprehensive Cancer Center of Northwetern University/Bruce Brockstein, MD

H. Lee Moffitt Cancer Center & Research Institute/Tawee Tanvetyanon, MD

University of Tennessee Cancer Institute/Furhan Yunus, MD

UNMC Eppley Cancer Center at The Nebraska Medical Center/Sandeep Rajan, MD

INVESTIGATOR

MEMBER INSTITUTION

STUDY

Marc C.Chamberlain, MD

University of Washington

A Phase II Study of Bendamustine (Cephalon, Inc.) in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)

John C. Grecula, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy (SRT) for Patients with 1-3 Brain Metatases from Solid Malignancies

Rachel M. Layman, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer

Edward Pan, MD

H. Lee Moffitt Cancer Center & Research Institute

Phase I Study of Bendamustine with Concurrent Whole Brain Radiation Therapy in Patients with Brain Metastases from Solid Tumors

Francisco Robert, MD

University of Alabama at Birmingham Comprehensive Cancer Center

UAB 0818 - Phase I/IIa Study of the Novel Combination of Bendamustine with Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients with Extensive Stage Small Cell Lung Cancer

John R. Adler, Jr., MD

Stanford Comprehensive Cancer Center

Phase I/II Trial of Vorinostat Concurrent with Radiotherapy in Treatment of Brain Metastases from Non-Small Cell Lung Cancer

Emily Chan, MD, PhD

Vanderbilt-Ingram Cancer Center

Phase I Trial of Chemoradiation with Capecitabine and Vorinostat in Pancreatic Cancer

Ranee Mehra, MD

Fox Chase Cancer Center

Phase I Study of the HDAC Inhibitor Vorinostat with Chemotherapy and Radiation Therapy for the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Theodoros N. Teknos, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

A Phase I/II Trial of Vorinostat in the Treatment of Advanced Oropharyngeal Carcinoma of the Head and Neck

Jeffrey Allen, MD

University of Tennessee Cancer Institute

A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Andrew Armstrong, MD

Duke Comprehensive Cancer Center

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology in Castration Resistant Metastatic Prostate Cancer: A Pilot Study

Oren J. Becher, MD

Memorial Sloan-Kettering Cancer Center

Phase I Trial of Perifosine + Temsirolimus for Recurrent Solid Tumors in Pediatrics

Susana M. Campos, MD, MPH

Dana-Farber/ Brigham and Women's Cancer Center

The Safety and Efficacy of Combination Therapy with AZD2171 and Temsirolimus in Patients with Recurrent Gynecological Malignancies

Sarat Chandarlapaty, MD, PhD

Memorial Sloan-Kettering Cancer Center

A Phase I/II Trial of Temsirolimus plus Neratinib in Patients with Metastatic HER2-Amplified or Triple Negative-EGFR Expressing Breast Cancer

Warren A. Chow, MD

City of Hope Comprehensive Cancer Center

Phase II Trial of Temsirolimus and AZD6244 for Soft-Tissue Sarcomas

Matthew G. Fury, MD, PhD

Memorial Sloan-Kettering Cancer Center

Phase I/II Study of Temsirolimus + Paclitaxel + Carboplatin in Advanced HNSCC

David Loeb, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Temsirolimus Augmentation of Chemotherapy for High Risk Sarcomas

Halla Nimeiri, MD

Robert H. Lurie Compehensive Cancer Center of Northwestern University

A Phase I/II Study of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

Eric Sherman, MD

Memorial Sloan-Kettering Cancer Center

Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Sandhya Srinivas, MD

Stanford Comprehensive Cancer Center

Using Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients with Castration-Resistant Prostate Cancer

Alan Venook, MD

UCSF Helen Diller Family Comprehensive Cancer Center

A Phase I/II Study of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma